Elk Creek Partners LLC raised its holdings in shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) by 10.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 612,049 shares of the company’s stock after buying an additional 59,393 shares during the period. Pacira Pharmaceuticals comprises 1.4% of Elk Creek Partners LLC’s portfolio, making the stock its 12th largest holding. Elk Creek Partners LLC owned 1.51% of Pacira Pharmaceuticals worth $22,982,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Principal Financial Group Inc. purchased a new stake in shares of Pacira Pharmaceuticals in the first quarter worth $237,000. Russell Investments Group Ltd. grew its stake in Pacira Pharmaceuticals by 3,599.8% during the second quarter. Russell Investments Group Ltd. now owns 283,513 shares of the company’s stock valued at $13,524,000 after acquiring an additional 275,850 shares in the last quarter. Benjamin F. Edwards & Company Inc. grew its stake in Pacira Pharmaceuticals by 12.2% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 2,794 shares of the company’s stock valued at $133,000 after acquiring an additional 303 shares in the last quarter. Lebenthal Lisanti Capital Growth LLC grew its stake in Pacira Pharmaceuticals by 61.8% during the second quarter. Lebenthal Lisanti Capital Growth LLC now owns 16,700 shares of the company’s stock valued at $797,000 after acquiring an additional 6,380 shares in the last quarter. Finally, Suffolk Capital Management LLC grew its stake in Pacira Pharmaceuticals by 8.2% during the second quarter. Suffolk Capital Management LLC now owns 32,360 shares of the company’s stock valued at $1,544,000 after acquiring an additional 2,457 shares in the last quarter.

Pacira Pharmaceuticals, Inc. (PCRX) traded up $0.10 during mid-day trading on Friday, reaching $46.20. 456,000 shares of the company’s stock traded hands, compared to its average volume of 840,943. Pacira Pharmaceuticals, Inc. has a fifty-two week low of $29.81 and a fifty-two week high of $58.95. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.99 and a quick ratio of 6.24.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings data on Wednesday, November 8th. The company reported $0.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The business had revenue of $67.30 million during the quarter, compared to analyst estimates of $68.99 million. During the same quarter last year, the business earned $0.20 earnings per share. Pacira Pharmaceuticals’s quarterly revenue was down 1.6% compared to the same quarter last year. research analysts anticipate that Pacira Pharmaceuticals, Inc. will post -0.85 EPS for the current fiscal year.

Several equities analysts recently weighed in on PCRX shares. Canaccord Genuity cut their target price on shares of Pacira Pharmaceuticals from $56.00 to $48.00 and set a “buy” rating for the company in a research note on Tuesday, August 29th. Mizuho reaffirmed a “buy” rating and set a $53.00 target price (down from $54.00) on shares of Pacira Pharmaceuticals in a research note on Tuesday, August 22nd. Needham & Company LLC started coverage on shares of Pacira Pharmaceuticals in a research note on Tuesday, August 22nd. They set a “buy” rating and a $55.00 target price for the company. HC Wainwright set a $59.00 target price on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. Finally, Jefferies Group reaffirmed a “buy” rating and set a $59.00 target price on shares of Pacira Pharmaceuticals in a research note on Thursday, September 7th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and eight have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $48.86.

In related news, SVP James B. Jones sold 850 shares of the firm’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $41.11, for a total value of $34,943.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO David M. Stack sold 58,885 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $38.34, for a total transaction of $2,257,650.90. Following the completion of the transaction, the chief executive officer now directly owns 159,164 shares in the company, valued at approximately $6,102,347.76. The disclosure for this sale can be found here. Insiders have sold 69,735 shares of company stock valued at $2,692,594 in the last quarter. 6.60% of the stock is owned by company insiders.

WARNING: “Elk Creek Partners LLC Increases Holdings in Pacira Pharmaceuticals, Inc. (PCRX)” was reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/elk-creek-partners-llc-increases-holdings-in-pacira-pharmaceuticals-inc-pcrx/1736712.html.

Pacira Pharmaceuticals Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.